DK3271357T3 - Fusionerede bicykliske heteroarylderivater med aktivitet som phd-inhibitorer - Google Patents

Fusionerede bicykliske heteroarylderivater med aktivitet som phd-inhibitorer Download PDF

Info

Publication number
DK3271357T3
DK3271357T3 DK16715122.4T DK16715122T DK3271357T3 DK 3271357 T3 DK3271357 T3 DK 3271357T3 DK 16715122 T DK16715122 T DK 16715122T DK 3271357 T3 DK3271357 T3 DK 3271357T3
Authority
DK
Denmark
Prior art keywords
heteroeer
bicycle
merged
derivatives
phd inhibitors
Prior art date
Application number
DK16715122.4T
Other languages
Danish (da)
English (en)
Inventor
Gregory Barker
Hannah Canning
Richard Davenport
David Harrison
Kerry Jenkins
David Livermore
Susanne Wright
Natasha Kinsella
Saleh Ahmed
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of DK3271357T3 publication Critical patent/DK3271357T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK16715122.4T 2015-03-18 2016-03-17 Fusionerede bicykliske heteroarylderivater med aktivitet som phd-inhibitorer DK3271357T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds
PCT/JP2016/059782 WO2016148306A1 (en) 2015-03-18 2016-03-17 Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Publications (1)

Publication Number Publication Date
DK3271357T3 true DK3271357T3 (da) 2020-02-17

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16715122.4T DK3271357T3 (da) 2015-03-18 2016-03-17 Fusionerede bicykliske heteroarylderivater med aktivitet som phd-inhibitorer

Country Status (31)

Country Link
US (1) US10287286B2 (cg-RX-API-DMAC7.html)
EP (1) EP3271357B1 (cg-RX-API-DMAC7.html)
JP (1) JP6726681B2 (cg-RX-API-DMAC7.html)
KR (1) KR102609431B1 (cg-RX-API-DMAC7.html)
CN (1) CN107531698B (cg-RX-API-DMAC7.html)
AU (1) AU2016234209B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017019653B1 (cg-RX-API-DMAC7.html)
CA (1) CA2979024C (cg-RX-API-DMAC7.html)
CL (1) CL2017002354A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017009353A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170468A (cg-RX-API-DMAC7.html)
DK (1) DK3271357T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2017000209A (cg-RX-API-DMAC7.html)
EA (1) EA035739B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17069696A (cg-RX-API-DMAC7.html)
ES (1) ES2774052T3 (cg-RX-API-DMAC7.html)
GB (1) GB201504565D0 (cg-RX-API-DMAC7.html)
GE (1) GEP20207095B (cg-RX-API-DMAC7.html)
HU (1) HUE047918T2 (cg-RX-API-DMAC7.html)
IL (1) IL254277B (cg-RX-API-DMAC7.html)
MX (1) MX2017011902A (cg-RX-API-DMAC7.html)
MY (1) MY194873A (cg-RX-API-DMAC7.html)
NZ (1) NZ735631A (cg-RX-API-DMAC7.html)
PE (1) PE20180656A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501699B1 (cg-RX-API-DMAC7.html)
PT (1) PT3271357T (cg-RX-API-DMAC7.html)
SG (1) SG11201707280VA (cg-RX-API-DMAC7.html)
TN (1) TN2017000384A1 (cg-RX-API-DMAC7.html)
UA (1) UA123668C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016148306A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201706612B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12454516B2 (en) 2021-12-28 2025-10-28 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017222417B2 (en) 2016-02-24 2020-07-09 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl derivatives as JAK-inhibitors
US11254668B2 (en) 2017-08-14 2022-02-22 Pfizer Inc. Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
IL281391B2 (en) 2018-09-13 2025-04-01 Kissei Pharmaceutical Imidazopyridinone compound
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
EP4122928A4 (en) * 2020-04-20 2023-12-13 Shenzhen TargetRx, Inc. SOLID FORM OF PYRAZINE SUBSTITUTED NICOTINAMIDE AND PRODUCTION AND USE THEREOF
AR123848A1 (es) * 2020-10-20 2023-01-18 Amgen Inc Compuestos espiro heterocíclicos y métodos de uso
TW202334134A (zh) 2021-10-28 2023-09-01 香港商英矽智能科技知識產權有限公司 含脯胺醯羥化酶結構域之蛋白質(phd)抑制劑及其用途
JP2025500892A (ja) * 2021-12-17 2025-01-15 アケビア セラピューティクス インコーポレイテッド 選択的phd1阻害剤化合物、組成物、及び使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
NZ523807A (en) 2000-06-30 2004-09-24 Wyeth Corp Substituted-triazolopyrimidines as anticancer agents
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
AR077417A1 (es) * 2009-07-17 2011-08-24 Japan Tobacco Inc Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa o agente inductor de la produccion de eritropoyetina
JP2011168582A (ja) 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
US20150239889A1 (en) 2012-08-23 2015-08-27 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compound

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
US12454516B2 (en) 2021-12-28 2025-10-28 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Also Published As

Publication number Publication date
EP3271357A1 (en) 2018-01-24
PH12017501699B1 (en) 2023-06-30
PH12017501699A1 (en) 2018-03-12
EA201792057A1 (ru) 2018-04-30
AU2016234209B2 (en) 2020-08-27
US10287286B2 (en) 2019-05-14
GEP20207095B (en) 2020-04-10
ES2774052T3 (es) 2020-07-16
ECSP17069696A (es) 2018-02-28
CR20170468A (es) 2018-04-27
PE20180656A1 (es) 2018-04-17
NZ735631A (en) 2023-07-28
PT3271357T (pt) 2020-02-21
JP6726681B2 (ja) 2020-07-22
CN107531698A (zh) 2018-01-02
KR20170129874A (ko) 2017-11-27
CL2017002354A1 (es) 2018-05-04
UA123668C2 (uk) 2021-05-12
GB201504565D0 (en) 2015-05-06
MY194873A (en) 2022-12-21
AU2016234209A1 (en) 2017-10-12
IL254277B (en) 2020-10-29
KR102609431B1 (ko) 2023-12-04
EA035739B1 (ru) 2020-08-03
HUE047918T2 (hu) 2020-05-28
DOP2017000209A (es) 2017-10-15
MX2017011902A (es) 2017-12-15
SG11201707280VA (en) 2017-10-30
EP3271357B1 (en) 2019-11-27
CA2979024C (en) 2024-02-20
TN2017000384A1 (en) 2019-01-16
ZA201706612B (en) 2019-01-30
BR112017019653B1 (pt) 2023-10-03
JP2018512408A (ja) 2018-05-17
WO2016148306A1 (en) 2016-09-22
CO2017009353A2 (es) 2017-11-30
US20180072714A1 (en) 2018-03-15
CA2979024A1 (en) 2016-09-22
CN107531698B (zh) 2024-08-13
IL254277A0 (en) 2017-10-31
BR112017019653A2 (pt) 2018-05-15
HK1249512A1 (en) 2018-11-02

Similar Documents

Publication Publication Date Title
DK3271357T3 (da) Fusionerede bicykliske heteroarylderivater med aktivitet som phd-inhibitorer
FIC20240025I1 (fi) Momelotinibi, mukaanlukien momelotinibidihydrokloridimonohydraatti
DK3464271T3 (da) Pyrazolderivater som plasma-kallikreininhibitorer
DK3324977T3 (da) Benzodiazepinderivater som rsv-inhibitorer
DK3319956T3 (da) Substituerede oxopyridinderivater
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3298002T3 (da) Heterocykliske amider som kinasehæmmere
DK3302448T3 (da) Erstattede heterocyclylafledninger som cdk-inhibitore
DK3313832T3 (da) 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
DK3271349T3 (da) Benzimidazolederivater som bromodomain-inhibitorer
EP3347008A4 (en) BETA-Lactamase INHIBITORS
DK3527263T3 (da) Bipyrazolderivater som jak-inhibitorer
IL254779A0 (en) Methods of administering glutaminase inhibitors
EP3313825A4 (en) Glucose uptake inhibitors
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
LT3371168T (lt) Indolin-2-ono dariniai
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
EP3615525C0 (en) PYRROLE DERIVATIVES AS PLK1 INHIBITORS
DK3319970T3 (da) Pyrido-oxazinonderivater som tnap-hæmmere
DK3372589T3 (da) Pyrimidinderivat
DK3371163T3 (da) Pyrrolidinderivater